An announcement from Invex Therapeutics Ltd. ( (AU:IXC) ) is now available.
Invex Therapeutics Ltd announced an expansion of its research collaboration with Tessara Therapeutics to further investigate the effects of Exenatide on Alzheimer’s Disease models, aiming to gain insights into its potential benefits on neural networks and gene expression. The company also reported prudent cash management with a closing balance of $5.7 million and highlighted a UK R&D tax incentive receipt, while continuing to explore additional asset opportunities.
More about Invex Therapeutics Ltd.
Invex Therapeutics Ltd is a biopharmaceutical company specializing in the development and commercialization of Exenatide for neurological conditions related to raised intracranial pressure.
YTD Price Performance: -2.86%
Average Trading Volume: 31,698
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$5.11M
Learn more about IXC stock on TipRanks’ Stock Analysis page.